Table 2.
Associations between clinicopathological variables and p53 functionality
| p53 non functional N (%) | p53 functional N (%) | p value | |
|---|---|---|---|
|
TP53 mutational status |
|
|
|
| wt |
7 (33) |
14 (78) |
0.01 |
| mut |
14 (67) |
4 (22) |
|
|
P53 IHC |
|
|
|
| 0 |
3 (11) |
7 (24) |
<0.001# |
| 0 - ≤25% |
1 (3) |
22 (76) |
|
| >25% |
24 (86) |
0 (0) |
|
|
Chr. 17 p status |
|
|
|
| AB |
5 (18) |
22 (76) |
<0.001* |
| LOH |
2 (7) |
4 (14) |
|
| Copy neutral LOH |
9 (32) |
0 (0) |
|
| Amplified LOH |
5 (18) |
1 (3) |
|
| Allelic Imbalance |
1(4) |
0 (0) |
|
| Two clones |
6 (21) |
2 (7) |
|
|
Age category |
|
|
|
| 50 – 59 |
4 (14) |
6 (22) |
NS |
| 60 – 69 |
10 (36) |
9 (32) |
|
| 70 – 79 |
10 (36) |
9 (32) |
|
| 80 – 89 |
4 (14) |
4 (14) |
|
|
DNA index |
|
|
|
| 0.95 – 1.05 |
6 (22) |
21 (78) |
<0.001¶ |
| 1.06 – 1.4 |
4 (15) |
3 (11) |
|
| 1.41 – 1.95 |
17 (63) |
3 (11) |
|
|
MMR status |
|
|
|
| MSI |
4 (14) |
14 (50) |
0.009 |
| MSS |
24 (86) |
14 (50) |
|
|
Gender |
|
|
|
| Male |
12 (43) |
18 (62) |
NS |
| Female |
16 (57) |
11 (38) |
|
|
Tumor Location |
|
|
|
| Right |
10 (36) |
19 (66) |
0.035 |
| Left |
18 (64) |
10 (34) |
|
|
Stage |
|
|
|
| I and II |
14 (50) |
22 (76) |
0.06 |
| III |
14 (50) |
7 (24) |
|
| Median Follow up in months | 66.75 | 89.77 | 0.4 |
*Χ2 test allelic status AB vs. LOH p=0.58; AB vs. CNLOH p<0.001; AB vs. ALOH p=0.005; AB vs. two clones p=0.006
LOH vs. CNLOH p=0.01; LOH vs. ALOH p=0.24; LOH vs. two clones p=0.28.
ALOH vs. CNLOH p=0.43; Amp LOH vs. two clones p=1.
CNLOH vs. two clones p=0.48.
# Χ2 test p53 IHC 0 vs. 0-25% p=0.07; 0 vs. >25% p<0.001; 0-25% vs. >25% p=0.001.
¶ Χ2 test DNA index 0.95 – 1.05 vs. 1.06 – 1.4 p=0.16; 0.95 – 1.05 vs. 1.41- 1.95 p<0.001; 1.06 – 1.40 vs. 1.41 – 1.95 p=0.29.